Evidence map›Paper›PMID 38765788›Full record

ArticlePharmacogenomics and personalized medicine2024

Evaluation of

Jun Mei Teng, Shuiqing Qin, Danyu Lu, Yefa Gu, Shi Jie Tang, Qiong Yan, Jiawei Yao, Chao Zhang

Abstract read
In one paragraph

Article in Pharmacogenomics and personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jun Mei TengLaboratory Department, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Shuiqing QinDepartment of Science and Education, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Danyu LuLaboratory Department, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Yefa GuDepartment of Psychiatry, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Shi Jie TangDepartment of Psychiatry, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Qiong YanLaboratory Department, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Jiawei YaoLaboratory Department, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Chao ZhangLaboratory Department, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the Patients and Methods: Between February and December 2022, 192 Zhuang and Han schizophrenia patients treated with VPA were studied. Steady-state VPA concentrations were determined using homogeneous enzyme immunoassays, and Results: The study identified five Conclusion: In Guangxi,

Indexed as

blood drug concentrationCYP2C19 geneHan Chinesevalproic acidZhuang Chinese

Identifiers

PMID38765788
PMCPMC11102100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.